Is MOTS-c Legal in South Carolina? How to Access It Legally

What Is MOTS-c and Why Does Its Legal Status Matter?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within mitochondrial DNA. Researchers first described it in a 2015 paper by Lee et al. Published in Cell Metabolism, which showed that systemic MOTS-c administration improved insulin sensitivity and reduced diet-induced obesity in mice (1). That finding sparked interest in MOTS-c as a potential metabolic and longevity-related therapy.

Interest is one thing. Legal status is another.

Why the Legal Question Is Not Straightforward

The United States has no single "peptide regulation" statute. Peptides fall under the same FD&C Act framework that governs all drugs, biologics, and compounded preparations. Because MOTS-c has never completed the FDA new drug application (NDA) process, it is not an FDA-approved drug product. That status has downstream consequences for how it can be manufactured, dispensed, and used in human patients.

South Carolina has its own pharmacy practice act (S.C. Code Ann. §§ 40-43-10 et seq.) and a medical practice act (S.C. Code Ann. §§ 40-47-10 et seq.), but neither statute creates a specific rule for unapproved peptides beyond what federal law already requires. The South Carolina Board of Pharmacy defers to FDA guidance on compounding of non-approved substances. That means the federal picture is where any analysis must start and, in practice, end.

Who Needs to Understand This

Patients researching MOTS-c for metabolic health, insulin resistance, or physical performance need to understand the legal framework before purchasing anything online. Clinicians in South Carolina who are considering adding peptide protocols to their practice also need clarity, because prescribing a non-approved compounded substance without following federal rules creates both regulatory and liability exposure.

Federal Regulatory Framework for MOTS-c

The FDA does not regulate MOTS-c as an approved drug. It regulates it as a bulk drug substance that compounding pharmacies may (or may not) use, depending on the specific nomination and review status.

The 503A and 503B Compounding Distinction

Section 503A of the FD&C Act covers traditional compounding pharmacies that prepare customized medications for individual patients based on a valid prescription from a licensed practitioner. Section 503B covers outsourcing facilities that can produce larger batches without patient-specific prescriptions but must register with the FDA and follow Current Good Manufacturing Practice (CGMP) standards (2).

For a 503A pharmacy to legally compound a substance, that substance generally must:

• Appear on the FDA's 503A Bulks List (also called the 503A Nominated Substances list) with a positive determination, OR
• Be a component of an FDA-approved drug, OR
• Meet other narrow criteria under 21 U.S.C. § 353a.

MOTS-c has been nominated for inclusion on the 503A Bulks List, placing it in Category 1 (substances that have been nominated and are under review). As of the most recent FDA update, the agency has not issued a final positive determination for MOTS-c. Without that determination, 503A pharmacies operating in strict compliance cannot compound MOTS-c for patient dispensing (3).

503B outsourcing facilities face an analogous framework under the 503B Bulks List. MOTS-c is not on the finalized 503B list, which means outsourcing facilities also cannot legally produce it for clinical distribution (4).

What FDA Enforcement History Tells Us

The FDA's 2023 and 2024 warning letters to peptide compounders made clear that the agency views unapproved bulk peptides as a significant compliance risk. While MOTS-c has not been the specific subject of a public warning letter at the time of this writing, the FDA's general enforcement posture toward non-approved peptide compounding is well-documented through letters targeting BPC-157, TB-500 (thymosin beta-4 fragments), and similar substances (5).

The FDA stated in its 2023 guidance framework: "Bulk drug substances that have not been evaluated and placed on the lists referenced in sections 503A(b) and 503B(a)(6) of the FD&C Act do not meet the conditions for inclusion under those provisions and may not be used in compounding." That language applies directly to MOTS-c given its pending review status.

South Carolina State Law: What It Adds (and What It Does Not)

South Carolina does not have a state statute that independently bans or permits MOTS-c. The state pharmacy board's authority over compounding tracks closely with federal standards, and the South Carolina Board of Pharmacy has historically aligned its guidance on non-approved compounded substances with FDA policy.

South Carolina Board of Pharmacy Position

The South Carolina Board of Pharmacy requires that all compounding pharmacies operating in the state maintain compliance with both state law and federal law, including the FD&C Act's compounding provisions. A pharmacy that compounds MOTS-c without a positive FDA bulk-substance determination is exposed to enforcement action under state law as well, because that activity would constitute compounding without proper authority under 21 U.S.C. § 353a (6).

South Carolina also adopted portions of the National Association of Boards of Pharmacy (NABP) model act, which reinforces federal standards for non-sterile and sterile compounding.

South Carolina Medical Practice Act

A South Carolina licensed physician (M.D. Or D.O.) may, under the medical practice act, prescribe any legal substance within the scope of their clinical judgment. The question of legality for MOTS-c compounding, however, returns to the federal framework: if the pharmacy cannot legally compound it, a prescription does not cure that problem. The physician's prescription is a necessary but not sufficient condition for legal access.

No State-Level Research Chemical Exemption

Some patients encounter MOTS-c marketed as a "research chemical" and wonder whether South Carolina law permits personal importation or possession for self-use under that label. South Carolina has no such exemption. If a substance is intended for human use, it falls under the FD&C Act's drug provisions regardless of how it is labeled at the point of sale (7).

Clinical Evidence: What We Actually Know About MOTS-c

Before deciding whether to pursue MOTS-c access, patients and clinicians should understand how limited the human evidence currently is.

Animal and In-Vitro Data

The 2015 Cell Metabolism paper by Lee et al. (referenced above) showed that MOTS-c administered to high-fat-diet mice for 3 weeks reduced body weight by approximately 5% relative to controls and improved glucose tolerance (1). A 2019 study in Nature Communications (Reynolds et al.) found that exogenous MOTS-c administration extended lifespan and improved metabolic function in aged male mice (8). These are encouraging findings. They are also mouse data.

Human Studies: Early and Small

A 2021 study published in Aging (Bhaskaran et al.) measured circulating MOTS-c levels in humans and found that plasma MOTS-c concentrations were significantly lower in older adults (mean age 70) compared with younger adults (mean age 25), with a mean difference of approximately 38 pg/mL (P<0.01) (9). The observation supports the hypothesis that declining MOTS-c may contribute to age-related metabolic changes. It does not establish that exogenous MOTS-c supplementation is safe or effective in humans.

No large randomized controlled trial of MOTS-c in human subjects has been completed and published as of this article's last review date. The absence of Phase 2 or Phase 3 trial data is one reason the FDA has not approved MOTS-c and has not finalized a positive bulk-substance determination.

What Clinicians Should Tell Patients

A useful clinical framework for conversations about MOTS-c involves three tiers of evidence evaluation:

Tier 1: Mechanism supported. The basic science showing MOTS-c interacts with AMPK pathways and influences mitochondrial function is reasonably well-established in cell and animal models (10).

Tier 2: Human pharmacokinetics unknown. No published study has established optimal dosing, injection frequency, or bioavailability data in human subjects. Doses used in clinical settings are extrapolated from animal studies, which introduces real uncertainty.

Tier 3: Long-term safety data absent. No study has followed human MOTS-c users for more than a short observation window. Clinicians should communicate this explicitly before any patient proceeds.

This tiered assessment does not tell a patient "no." It gives them the information to make a decision with accurate expectations.

Practical Paths to Legal Access in South Carolina

Given the federal framework, there are a small number of legitimate paths a South Carolina patient could pursue.

Path 1: Clinical Trial Enrollment

The most legally and scientifically sound route is enrollment in a registered clinical trial. ClinicalTrials.gov lists ongoing investigations of MOTS-c and related mitochondrial peptides. Patients who qualify for a trial receive the peptide under Investigational New Drug (IND) protocols, with full informed consent, physician oversight, and regulatory cover (11). This path is limited by eligibility criteria and trial availability, but it is the correct answer for patients who want both legal clarity and scientific rigor.

Path 2: Physician Oversight Through a 503A Pharmacy Operating in a Gray Zone

Some 503A compounding pharmacies have continued to compound MOTS-c on the basis that the FDA's bulk-list review is not yet finalized as a negative determination. This is a contested legal position. The FDA's stated policy, as described above, requires a positive determination before compounding is authorized. Patients and physicians who use this path accept meaningful regulatory risk.

If a South Carolina patient and their physician choose this route, they should at minimum verify that the compounding pharmacy:

• Holds an active license with the South Carolina Board of Pharmacy or is licensed to ship into South Carolina.
• Compounds MOTS-c under sterile conditions with third-party potency and endotoxin testing.
• Provides a Certificate of Analysis (CoA) for each batch.
• Operates under a valid patient-specific prescription from a licensed South Carolina clinician.

Path 3: Telehealth Consultation with a Licensed SC Physician

South Carolina's telehealth laws allow patients to consult with licensed South Carolina physicians via video or secure messaging platforms without an in-person visit for most non-controlled-substance consultations. The South Carolina Telehealth Alliance and the South Carolina Department of Health and Environmental Control (DHEC) both provide guidance on telehealth practice standards (12). A telehealth physician can evaluate a patient's metabolic health profile, review labs, and determine whether MOTS-c is appropriate, within the same legal constraints that apply to in-person prescribing.

Path 4: Avoid Unregulated Online Sources

Purchasing MOTS-c from unregulated online vendors (often labeled "for research use only") and self-administering it is not a legal path to human use. The FDA has taken action against suppliers of research-labeled peptides that were clearly marketed for human use. Beyond the legal issue, unregulated sources carry real safety risks: independent testing of peptides purchased online has repeatedly found incorrect concentrations, bacterial contamination, and undisclosed additives (13).

How South Carolina Compares to Other States

South Carolina's framework is not unique. The FDA's rules apply in all 50 states, and no state has successfully carved out a blanket exemption for non-approved peptide compounding. Some states with larger compounding pharmacy industries (Texas, Florida, Colorado) have more pharmacies willing to operate in the gray zone, but the underlying federal risk is identical regardless of state.

South Carolina has a smaller specialty compounding pharmacy market than those states, which means patients may find fewer local options willing to compound MOTS-c. Telehealth platforms connected to out-of-state compounding pharmacies licensed to ship into South Carolina can partially bridge that gap.

Red Flags to Watch for When Seeking MOTS-c

Patients in South Carolina who encounter the following should treat them as warning signs that a provider or pharmacy may not be operating within legal bounds:

No physician consultation required. Any vendor selling injectable MOTS-c directly to consumers without requiring a valid prescription is operating outside the law.

No CoA provided. Legitimate compounding pharmacies provide batch-specific Certificates of Analysis showing potency, sterility, and endotoxin testing results. Refusal to provide one is a quality-control red flag.

Vague dosing instructions. Because human pharmacokinetic data for MOTS-c is limited, any provider offering highly confident dosing protocols without acknowledging the evidence gaps deserves scrutiny.

"Guaranteed results" claims. No legitimate clinician makes outcome guarantees for a peptide in early-stage human research.

Questions to Ask Your South Carolina Provider

If you are working with a South Carolina clinician who proposes MOTS-c, these questions help establish whether they are operating within a defensible clinical and legal framework:

1. Which compounding pharmacy will fill the prescription, and is it licensed in South Carolina?
2. Can you provide the pharmacy's most recent Certificate of Analysis for MOTS-c?
3. What human safety data are you basing your dosing recommendation on?
4. How will we monitor my response and watch for adverse effects?
5. What is the plan if the FDA issues a negative determination for MOTS-c on the bulk-substances list?

A clinician who cannot answer questions 1 and 2 specifically is not positioned to prescribe MOTS-c safely.